Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)4267-4277
Number of pages11
JournalBlood advances
Volume4
Issue number18
DOIs
Publication statusPublished - 22 Sep 2020

Keywords

  • ACUTE MYELOID-LEUKEMIA
  • MINIMAL RESIDUAL DISEASE
  • HYPOMETHYLATING AGENT THERAPY
  • CONVENTIONAL CARE REGIMENS
  • MYELODYSPLASTIC SYNDROME
  • AZACITIDINE THERAPY
  • TREATMENT RESPONSE
  • CLINICAL-RESPONSE
  • SURVIVAL
  • TRIAL

Cite this